O.D. Bragina(1), V.I. Chernov(1, 2), M.S. Larkina(3), R.V. Zelchan(1), I.G. Sinilkin(1), A.A. Medvedeva(1) 1-Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 5, Kooperativnaya str., Tomsk, 634009, Russian Federation; 2-National Research Tomsk Polytechnic University, 30, Lenina Avenue, Tomsk, 634050, Russian Federation; 3Siberian State Medical University, 2, Moskovsky trakt, Tomsk, 634055, Russian Federation E-mail: [email protected]

Diagnosis and determination of tumor process in patients with prostate cancer are the most urgent problems of modern оncology. Prostate-specific membrane antigen (PSMA) is one of the most promising molecular targets for the diagnosis of prostate cancer. The level of PSMA in prostate cancer is higher than the expression in normal tissues and different types of dysplasia and is associated with the stage, the degree of malignancy and aggressiveness of the tumor process. In recent years for the detection of specific tumor targets there are actively developed non-invasive radionuclide imaging techniques using radioisotopes, the application of which allows not only estimating the prevalence of malignancy (primary tumor site, regional lymph nodes and distant organs and tissues) but also performing multiple tests for the treatment evaluation. Recently, low molecular weight peptides have been used as a targeting module, the main advantages of which there is the possibility of forming strong bonds with chelating agents, small sizes, promoting fast pharmacokinetics and high tissue penetration, as well as the stability and relatively simple conditions of synthesis. This review describes the main radiopharmaceuticals mainly based on low molecular weight peptides, targeted to PSMA and used for diagnosis of prostate cancer.
prostate cancer, prostate-specific membrane antigen, antibodies, low molecular weight peptides, radionuclide diagnostics

Список литературы: 
  1. Imyanitov E.N. E`pidemiologiya i biologiya raka prostaty. Prakticheskaya onkologiya. 2008; 9 (2): 57–64. [Imyanitov E.N. Epidemiology and biology of prostate cancer. Practiceskaya oncologiya. 2008; 9 (2): 57–64 (in Russian)]
  2. Resnick M.J., Koyama T., Fan K.H., Albertsen P.C., Goodman M., Hamilton A.S., Long-term functional outcomes after treatment for localized prostate cancer. N. Engl. J. Med. 2013; 368: 436–45.
  3. Pinto F., Totaro A., Palermo G., Calarco A., Sacco E., D’Addessi A., Imaging in prostate cancer staging: present role and future perspectives. Urol. Int. 2012; 88: 125–36.
  4. Lees K., Durve M., Parker C. Active surveillance in prostate cancer: patient selection and triggers for intervention. Curr. Opin. Urol. 2012; 22: 210–5.
  5. Ross A.E., Loeb S., Landis P., Partin A.W., Epstein J.I., Kettermann A., et al. Prostate-specific antigen kinetics during follow-up area unreliable trigger for intervention in a prostate cancer surveillance program. J. Clin. Oncol. 2010; 28: 2810–6.
  6. Vorob`ev A.V., Krzhivickiy P.I. Perspektivy profilaktiki, diagnostika i stadirovanie raka predstatel`noy zhelezy. Prakticheskaya onkologiya. 2008; 9 (2): 71–82. [Vorob`ev A.V., Krjivitskii P.I. Prospects for prevention, diagnosis and staging of prostate cancer. Practiceskaya oncologiya. 2008; 9 (2): 57–64 (in Russian)]
  7. Loblaw A., Zhang L., Lam A., Nam R., Mamedov A., Vesprini D., et al. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J. Urol. 2010; 184: 1942–6.
  8. Fall K., Garmo H., Andren O., Bill-Axelson A., Adolfsson J., Adami H.O., et al. Prostate- specific antigen levels as ap redictor of lethal prostate cancer. J. Natl. Cancer Inst. 2007; 99: 526–32.
  9. Haberkorn U., Eder M., Kopka K., Babich J.W. and Eisenhut M. New Strategies in Prostate Cancer: Prostate Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clin. Cancer Res. 2016; 22 (1): 9–15.
  10. Wang X., Tsui B., Ramamurthy G., Zhang P., Meyers J., Kenney M. E., Kiechle J., Ponsky L. and Basilion J. P. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen. Mol. Cancer Ther. 2016; 15 (8): 1834–44.
  11. Rajasekaran A. K., Anilkumar G. and Christiansen J. J. Is prostate-specific membrane antigen a multifunctional protein? Am. J. Physiol. Cell Physiol. 2005; 288: 975–81.
  12. Ristau B. T., O’Keefe D. S. and Bacich D. J. The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research. Urol. Oncol. 2014; 32 (3): 272–9.
  13. Chehonin V.P., Grigor`ev M.E`., Zhirkov Yu.A., Lebedev D.V. Prostaticheskiy specificheskiy membrannyy antigen i ego rol` v diagnostike raka predstatel`noy zhelezy. Voprosy medicinskoy himii. 2002; 48: 31–43. [Chehonin V.P., Grigorieiv M.E., Jerkov U.A., Lebedev D.V. The role of prostate specific membrane antigene in the diagnostic of prostate cancer. Voprosy medicinskoi khimii. 2002; 48: 3–8 (in Russian)]
  14. Chang S.S. Overview of Prostate-Specific Membrane Antigen. Reviews in urology. 2004; 6 (10): 13–8.
  15. Eder M., Eisenhut M., Babich J., Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur. J. Nucl. Med. Mol. Imaging. 2013; 40: 819–23.
  16. Kiess A.P., Banerjee S.R., Mease R.C., Rowe S.P., Rao A., Foss C.A., Chen Y., Yang X., Cho S.Y., Nimmagadda S. and Pomperq M.Q. Prostate-specific membrane antigen as a target for cancer imaging and therapy. J. Nucl. Med. Mol. Imaging. 2015; 59 (3): 241–68.
  17. Ristau B.T., O’Keefe D.S. and Bacich D.J. The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research. Urol. Oncol. 2014; 32 (3): 272–9.
  18. Osborne J.R., Akhtar N.H., Vallabhajosula S., Anand A., Deh K., Tagawa S.T. Prostate-specific membrane antigen-based imaging. Urol. Oncol. 2013; 31 (2): 144–54.
  19. Denmeade S.R., Mhaka A.M., Rosen D.M., Brennen W.N., Dalrymple S., Dach I., Olesen C., Gurel B., Demarzo A.M., Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci. Transl. Med. 2012; 4 (140): 1–22.
  20. Bouchelouche K., Choyke P. L. and Capala J. Prostate Specific Membrane Antigen–A Target for Imaging and Therapy with Radionuclides. Discov. Med. 2010; 9 (44): 55–61.
  21. Mease R.C., Foss C.A. and Pomper M.G. PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen. Curr. Top. Med. Chem. 2013; 13 (8): 951–62.
  22. Chatalic K.L.S., Heskamp S., Konijnenberg M., Molkenboer-Kuenen J.D.M., Franssen G.M, Groningen M.C., Schottelius M., Wester H.J., Weerden W.M., Boerman O.C., Jong M. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics. 2016; 6 (6): 849–61.
  23. Chatalic K.L.S., Veldhoven-Zweistra J., Bolkestein M., Hoeben S., Koning G.A., Boerman O.C, Jong M. and Weerden W.M. A Novel 111In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. J. Nucl. Med. 2015; 56: 1094–9.
  24. Gourni E., Henriksen G. Metal-Based PSMA Radioligands. Molecules. 2017; 22 (523): 1–34.
  25. Lütje S., Heskamp S., Cornelissen A.S., Poeppel T.D., Broek S.A. M. W., Rosenbaum-Krumme S., Bockisch A., Gotthardt M., Rijpkema M., Boerman O.C. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics. 2015; 5 (12): 1388–401.
  26. Chernov V.I., Bragina O.D., Sinilkin I.G., Tickaya A.A., Zel`chan R.V. Radioimmunoterapiya v lechenii zlokachestvennyh obrazovaniy. Sibirskiy onkologicheskiy zhurnal. 2016; 15 (2): 101–6. [Chernov V.I., Bragina O.D., Sinilkin I.G., Tickaya A.A., Zel’chan R.V. Radioimmunotherapy in the treatment of malignant tumors. Sibirskij onkologicheskij zhurnal. 2016; 15 (2): 101–6 (in Russian)]
  27. Chernov V.I., Bragina O.D., Sinilkin I.G., Medvedeva A.A., Zel`chan R.V. Radionuklidnaya teranostika zlokachestvennyh obrazovaniy. Vestnik rentgenologii i radiologii. 2016; 97 (5): 306–13. [Chernov V.I., Bragina O.D., Sinilkin I.G., Medvedeva A.A., Zel’chan R.V. Radionuclide terorectics of malignant tumors. Vestnik rentgenologii i radiologii. 2016; 97 (5): 306–13 (in Russian)]
  28. Chernov V.I., Bragina O.D., Sinilkin I.G., Medvedeva A.A., Zel`chan R.V. Radioimmunoterapiya: sovremennoe sostoyanie problemy. Voprosy onkologii. 2016; 62 (1): 24–30. [Chernov V.I., Bragina O.D., Sinilkin I.G., Medvedeva A.A., Zel’chan R.V. Radioimmunotherapy: the current state of the problem. Voprosy onkologii. 2016; 62 (1): 24–30 (in Russian)]
  29. Bragina O.D., Lar`kina M.S., Stasyuk E.S., Chernov V.I., Yusubov M.S., Skuridin V.S., Deev S.M., Zel`chan R.V., Buldakov M.A., Podrezova E.V., Belousov M.V. Razrabotka vysokospecifichnogo radiohimicheskogo soedineniya na osnove mechenyh 99mTs rekombinantnyh adresnyh molekul dlya vizualizacii kletok s gipere`kspressiey Her-2/neu. Byulleten` sibirskoy mediciny. 2017; 16 (3): 25–33. [Bragina O.D., Larkina M.S., Stasyuk E.S., Chernov V.I., Yusubov M.S., Skuridin V.S., Deyev S.M., Zelchan R.V., Buldakov M.A., Podrezova E.V., Belousov M.V. Development of highly specific radiochemical compounds based on 99mTc-labeled recombinant molecules for targeted imaging of cells overexpressing Her-2/neu. Bulleten Sibirskoi Medicini. 2017; 16 (3): 25–33 (in Russian)]
  30. Larenkov A.A., Kodina G.E. Radionuklidnaya diagnostiki raka predstatel`noy zhelezy: pozitronnaya e`missionnaya tomografiya s 68Ga–PSMA-ingibitorami i ih farmrazrabotka. 2017. Medicinskaya radiologiya i radiacionnaya bezopasnost`. 2017; 62 (6): 58–74. [Larenkov A.A., Kodina G.E. Radionuclide Diagnosis of Prostate Cancer: Positron Emission Tomography with 68Ga-PSMA Inhibitors and Their Pharmaceutical Development. Medicinskaya radiologiya I radiacionnaya bezopastnost. 2017; 62 (6): 58–74 (in Russian)]
  31. Cho S.Y., Gage K.L., Mease R.C., Senthamizhchelvan S., Holt D.P., Jeffrey-Kwanisai A., Endres C.J., Dannals R.F., Sgouros G., Lodge M., Eisenberger M.A., Rodriguez R., Carducci M.A., Rojas C., Slusher B.S., Kozikowski A.P. and Pomper M.G. Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer. J. Nucl. Med. 2012; 53 (12): 1883–91.
  32. Afshar-Oromieh A., Malcher A., Eder M., Eisenhut M., Linhart H. G., Hadaschik B. A., Holland-Letz T., Giesel F. L., Kratochwil C., Haufe S., Haberkorn U., Zechmann C. M. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging. 2013; 40: 486–95.
  33. Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl. Radiat. Isot. 2013; 76: 55–62.
  34. Afshar-Oromieh A., Avtzi E., Giesel F.L., Holland-Letz T., Linhart H.G., Eder M., et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2015; 42: 197–209.
  35. Eiber M., Maurer T., Souvatzoglou M., Beer A.J., Ruffani A., Haller B., et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J. Nucl. Med. 2015; 56: 668–74.
  36. Chakraborty P.S., Kumar R., Tripathi M., Das C.J., Bal C. Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma. Clin. Nucl. Med. 2015; 40: 328–9.
  37. Uprimny C., Kroiss A., Nilica B., Buxbaum S., Decristoforo C., Horninger W., et al. (68)Ga-PSMA ligand PET versus (18)F-NaF PET: evaluation of response to (223)Ra therapy in a prostate cancer patient. Eur. J. Nucl .Med. Mol. Imaging. 2015; 42: 362–3.
  38. Chernov V.I., Medvedeva A.A., Sinilkin I.G., Zel`chan R.V., Bragina O.D., Skuridin V.S. Opyt razrabotki innovacionnyh radiofarmpreparatov v Tomskom NII onkologii. Sibirskiy onkologicheskiy zhurnal. 2015; 2: 45–7. [Chernov V.I., Medvedeva A.A., Sinilkin I.G., Zel’chan R.V., Bragina O.D., Skuridin V.S. Experience in the development of innovative radiopharmaceuticals in the Tomsk Institute of Oncology. Sibirskij onkologicheskij zhurnal. 2015; 2: 45–7 (in Russian)]
  39. Chernov V.I., Bragina O.D., Zel`chan R.V., Medvedeva A.A., Sinilkin I.G., Lar`kina M.S., Stasyuk E.S., Nesterov E.A., Skuridin V.S. Mechenye analogi somatostatina v teranostike neyroe`ndokrinnyh opuholey. Medicinskaya radiologiya i radiacionnaya bezopasnost`. 2017; 62 (3): 42–9. [Chernov V.I., Bragina O.D., Zel’chan R.V., Medvedeva A.A., Sinilkin I.G., Lar’kina M.S., Stasyuk E.S., Nesterov E.A., Skuridin V.S. Labeled Somatostatin Analogues in Theranostics of Neuroendocrine Tumors. Medicinskaya radiologiya I radiacionnaya bezopastnost. 2017; 62 (3): 42–9 (in Russian)]
  40. Humblet V., Misra P.and Frangioni J. V. An HPLC/Mass Spectrometry Platform for the Development of Multimodality Contrast Agents and Targeted Therapeutics: Prostate-Specific Membrane Antigen Small Molecule Derivatives. Contrast Media Mol. Imaging. 2006; 1 (5): 196–211.
  41. Vallabhajosula S., Nikolopoulou A., Babich J.W., Osborne J.R., Tagawa S.T., Lipai I., Solnes L., Maresca K.P., Armor T., Joyal J.L., Crummet R., Stubbs J.B., Goldsmith S.J. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J. 0Nucl. Med. 2014; 55 (11): 1791–8.
  42. Schmidkonz C., Hollweg C., Beck M., Reinfelder J., Goetz T.I., Sanders J.C., Schmidt D., Prante O., Bäuerle T., 99mTc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer. Prostate. 2018; 78 (1): 54–63.